AIMD — Ainos, Inc.
$0.8372-0.82%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for AIMD in the TickerWise workspace.
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 44
- Website: https://www.ainos.com
Latest SEC filings for AIMD
Latest AIMD news
- Ainos Completes VELDONA Technology Transfer, Triggering $600,000 License Payment Read article
- Ainos Completes Delivery of 1,400 AI Nose Systems to ASE Under $2.1 Million, Three-Year Contract Read article
- Ainos Details Partner-Funded VELDONA Development and Revenue Opportunities, Reinforcing Focus on Chemical Intelligence Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.